<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729339</url>
  </required_header>
  <id_info>
    <org_study_id>OMCP-97-011</org_study_id>
    <nct_id>NCT00729339</nct_id>
  </id_info>
  <brief_title>Role of Mosapride in Patients With Gastroesophageal Reflux Disease</brief_title>
  <official_title>Role of Mosapride in Patients With Gastroesophageal Reflux Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lotung Poh-Ai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tomorrow Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lotung Poh-Ai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastroesophageal reflux disease (GERD) is a very common disease in the Western World. In
      Taiwan, this disease is increasing gradually because the investigators' eating style is
      closing to Western world.

      Proton pump is the main drug for patients with GERD in the past two decades. Prokinetic agent
      is an important adjuvant to the therapy of GERD. This study aims to evaluate the role of
      prokinetic agent in the management of GERD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, cross-over study. FSSG is obtained at the beginning, one
      month and two months of the study.

      This study plans to enroll 100 patients with symptoms of GERD (acid regurgitation, belching,
      dysphagia). After receiving endoscopic examination, a frequent scale for the symptoms of
      gastroesophageal reflux disease (FSSG) is obtained from these patients. Fifty patients
      receive lansoprazole 30 mg once plus mosapride 5 mg tid daily in the first month; and
      lansoprazole 30 mg once plus placebo tid daily in the second month. Another fifty patients
      receive lansoprazole 30 mg once plus placebo tid daily in the first month; and lansoprazole
      30 mg once plus mosapride 5 mg tid daily in the second month.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom improvement evaluated by frequent scale for the symptoms of gastroesophageal reflux disease (FSSG)</measure>
    <time_frame>before enrollment, one month after treatment, two months after treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lansoprazole plus mosapride for the first month, and followed by lansoprazole plus placebo for the second month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lansoprazole plus placebo for the first month, and lansoprazole plus mosapride for the second month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mosapride for the first month and placebo for the 2nd month</intervention_name>
    <description>lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo for the first and mosapride for the second month</intervention_name>
    <description>lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 90 years old

          -  Outpatients

          -  Characteristic GERD symptoms: acid regurgitation, heart burn, or belching

          -  Erosive esophagitis on upper digestive endoscopy, based on Los Angeles classification

        Exclusion Criteria:

          -  History of allergy to lansoprazole or mosapride

          -  Pregnant or lactating women

          -  Uremia

          -  Decompensated liver disease

          -  Age under 18 and over 90 years-old

          -  Lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hwai-Jeng Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotung Poh-Ai Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lotung Poh-Ai Hospital</name>
      <address>
        <city>Lotung Town, Ilan County</city>
        <zip>265</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <last_update_submitted>May 12, 2009</last_update_submitted>
  <last_update_submitted_qc>May 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hsin-Hong Chen/Superintendent</name_title>
    <organization>Lotung Poh-Ai Hospital</organization>
  </responsible_party>
  <keyword>Gastroesophageal reflux disease</keyword>
  <keyword>Mosapride</keyword>
  <keyword>Lansoprazole</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Mosapride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

